Is there a source for TUDCA cycle support, and what dose and timing do labels and trials give?
| Product | Strength | Supplied as |
|---|---|---|
| Teofarma TAURO capsules (Italy) | 150 mg or 250 mg TUDCA dihydrate per hard capsule | Two blisters of 10 capsules1 |
| RELYVRIO (US) | 1 g taurursodiol with 3 g sodium phenylbutyrate per packet | Powder in single-dose packets, cartons of 7 or 562 |
The searches found no trial of TUDCA during a steroid or anabolic cycle; for biliary indications, the Teofarma capsule summary suggests 5-10 mg/kg/giorno (per day), in the majority of cases 250 to 750 mg a day, in divided doses after meals, set by the doctor on the patient's weight and how severe the condition is.1
What TUDCA products have a label
The table is set at the top of the page
The Teofarma summary gives its indication as altered bile secretion, including cholesterol-supersaturated bile and radiolucent gallstones, and it does not mention steroid or anabolic cycles.1 The FDA approved RELYVRIO for ALS in adults on September 29, 2022.3 On February 28, 2025, Amylyx asked FDA to withdraw approval after its 48-week phase 3 PHOENIX trial did not meet its prespecified primary and secondary endpoints, and FDA's notice withdraws the approval.3 The searches found no current US label for TUDCA alone.
Daily dose and timing in labels and trials
For biliary indications, Teofarma's summary suggests 5-10 mg/kg/giorno (per day), in the majority of cases 250 to 750 mg a day, in divided doses after meals and set by the doctor on the patient's weight and how severe the condition is.1 The RELYVRIO label, for ALS in adults, gives 1 packet (3 g sodium phenylbutyrate and 1 g taurursodiol) daily for the first 3 weeks, then 1 packet twice daily, before a snack or meal; the label gives 6 g sodium phenylbutyrate and 2 g taurursodiol as its maximum dose in humans, a fixed combination, not TUDCA alone.2
The sources disagree on the amount, and of the trials below, the Elia 2016 and Kars reports state that TUDCA was given by mouth.45
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Crosignani 1996, dose-response study6 | 500, 1000 or 1500 mg daily | 24 patients with primary biliary cirrhosis | six months |
| Crosignani 1998, multicenter trial7 | daily doses of 500 mg or 750 mg, or placebo | One hundred and fifty patients with chronic hepatitis (HCV-related, per the title) | 6 months |
| Ma 2016, Chinese phase 3 trial8 | 250 mg per dose, 3 times per day, against UDCA | 199 patients with primary biliary cholangitis | 24 weeks |
| Elia 2016, ALS phase 2 trial4 | 1 g twice daily by mouth, against placebo | 34 ALS patients on riluzole | 54 weeks |
| Kars, obesity trial5 | 1,750 mg/day by mouth, or placebo | Twenty obese adults | 4 weeks |
Milligram has no logged TUDCA dose pattern to report.
How the RELYVRIO combination powder is mixed
The RELYVRIO label, for its mix of taurursodiol with sodium phenylbutyrate, puts the contents of one packet into 8 ounces of room temperature water, stirred vigorously.2 The mixture is taken orally or by feeding tube within 1 hour.2 The searches found no leaflet or label that covers mixing loose TUDCA supplement powder.
Every TUDCA product in the sources is taken by mouth or by feeding tube, so there is no mg/mL concentration or U-100 syringe mark to give.
How TUDCA is stored
The RELYVRIO label gives 20°C to 25°C for unmixed packets, protected from moisture.2 The mixed suspension keeps up to 1 hour at room temperature, and unused suspension is discarded after 1 hour.2 The Teofarma summary says the capsules are kept at room temperature, with a shelf life of 36 months.1 The searches returned no stability data for TUDCA powder mixed in water beyond the label's own limit.
Safety and cycle use
The RELYVRIO label lists diarrhea, abdominal pain, nausea and upper respiratory tract infection as the most common adverse reactions with the combination (at least 15% and at least 5% greater than placebo).2 Teofarma's contraindications include known hypersensitivity to the components, active peptic ulcer, pregnancy and radiopaque gallstones; it describes tolerability at the doses it names as generally good, with occasional bowel irregularities, rare nausea, vomiting and loose stools, and reported cases of gallstone calcification.1 In Ma 2016, the 199-patient Chinese trial in primary biliary cholangitis, adverse events occurred in 44% of the TUDCA group and 40% of the UDCA group (P = 0.55), with 93.80% judged not related to the study medications.8 In Elia 2016, the 34-patient ALS trial, the report says TUDCA was well tolerated, with no between-group differences for adverse events, and in Crosignani 1996, the 24-patient dose-response study, diarrhea was the only side effect.46 The searches found no label or trial of TUDCA taken for "cycle support" as such.
References
- Teofarma S.r.l. Tauro_150_250_RCP_01_2014. teofarmasrl.it
- Amylyx Pharmaceuticals. RELYVRIO US Prescribing Information. amylyx.com
- Federal Register. This document is scheduled to be published in the. public-inspection.federalregister.gov
- PubMed Central. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. 2015. pmc.ncbi.nlm.nih.gov
- PubMed Central. Tauroursodeoxycholic Acid May Improve Liver and Muscle but Not Adipose Tissue Insulin Sensitivity in Obese Men and Women. 2010. pmc.ncbi.nlm.nih.gov
- PubMed. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. 1996. pubmed.ncbi.nlm.nih.gov
- PubMed. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study. 1998. pubmed.ncbi.nlm.nih.gov
- PubMed Central. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. 2016. pmc.ncbi.nlm.nih.gov